Natera Inc (NTRA) reported disappointing financial results for the third quarter of fiscal 2025, with earnings per share (EPS) of $-0.64, falling short of Wall Street's consensus estimate of $-0.38 by $0.26. Revenue for the quarter was $0.6 billion, exceeding expectations of $0.5 billion but still reflecting challenges within the company.
The company, headquartered in Austin, Texas, specializes in genetic testing services, leveraging its cfDNA technology platform to develop non-invasive prenatal tests, cancer care assays, and organ health assessments. With a market capitalization of $27.1 billion, Natera continues to focus on advancing its offerings in women's health and oncology.
Natera will host an earnings conference call after market close to discuss these results and provide further insights into its operational performance. Investors are encouraged to review the full earnings release and management commentary for additional context regarding the quarter's performance and future outlook.
Looking ahead, Natera's upcoming earnings dates are set for May 5, 2026, and August 4, 2026, with EPS estimates of $-0.4156 and $-0.4503, respectively. This update provides insight into Natera Inc's recent operational performance and financial health, as missing analyst expectations may reflect ongoing challenges in the business or market conditions.